Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Abeona Therapeutics (ABEO) Operating Expenses: 2011-2025

Historic Operating Expenses for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to $24.0 million.

  • Abeona Therapeutics' Operating Expenses rose 56.52% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.6 million, marking a year-over-year increase of 37.63%. This contributed to the annual value of $64.2 million for FY2024, which is 26.81% up from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' Operating Expenses is $24.0 million, which was up 3.56% from $23.2 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Operating Expenses ranged from a high of $49.7 million in Q4 2021 and a low of $9.0 million during Q2 2022.
  • Moreover, its 3-year median value for Operating Expenses was $15.3 million (2024), whereas its average is $16.5 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 184.05% in 2021, then crashed by 73.81% in 2022.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Operating Expenses stood at $49.7 million in 2021, then plummeted by 73.81% to $13.0 million in 2022, then climbed by 1.58% to $13.2 million in 2023, then grew by 26.22% to $16.7 million in 2024, then soared by 56.52% to $24.0 million in 2025.
  • Its Operating Expenses was $24.0 million in Q3 2025, compared to $23.2 million in Q2 2025 and $19.7 million in Q1 2025.